(R)-N-[11C]methyl-3-pyrrolidyl benzilate, a high-affinity reversible radioligand for PET studies of the muscarinic acetylcholine receptor

被引:11
作者
Skaddan, MB [1 ]
Jewett, DM [1 ]
Sherman, PS [1 ]
Kilbourn, MR [1 ]
机构
[1] Univ Michigan, Sch Med, Dept Radiol, Ann Arbor, MI 48109 USA
关键词
R-N-[C-11]methyl-3-pyrrolidyl benzilate; muscarinic acetylcholine receptor; phenserine; positron emission tomography;
D O I
10.1002/syn.10079
中图分类号
Q189 [神经科学];
学科分类号
071006 ;
摘要
We recently reported the synthesis and binding affinity of ligands for the muscarinic acetylcholine receptor (mAChR) based on both the pyrrolidyl and piperidyl benzilate scaffold. One of these, (R)-3-pyrrolidyl benzilate, was successfully radiolabeled with [C-11]methyl triflate and the resulting compound, (R)-N-[C-11]methyl-3-pyrrolidyl benzilate (3-[C-11]NMPYB), was evaluated as a reversible, acetylcholine-sensitive tracer for the mAChR (K-i of unlabeled 3-NMPYB is 0.72 nM). This compound displayed high, receptor-mediated retention in regions of the mouse and rat brain known to have high concentrations of mAChRs. Moreover, bolus studies in a pigtail monkey showed that this compound had superior clearance from the brain when compared to muscarinic radiotracers previously employed in human PET studies. Infusion studies in the same monkey revealed that it was possible to achieve equilibrium of radiotracer distribution for 3-[C-11]NMPYB in both the striatum and cortex. Sensitivity to endogenous acetylcholine levels was evaluated by injecting phenserine (5 mg/kg) into rats prior to administration of 3-[C-11]NMPYB in an equilibrium infusion protocol. This pretreatment produced a modest, statistically significant decrease (9-11%) in the distribution volume ratios for muscarinic receptor rich regions of the rat brain as compared to controls. (C) 2002 Wiley-Liss, Inc.
引用
收藏
页码:31 / 37
页数:7
相关论文
共 47 条
[1]   COMPARATIVE ALTERATIONS OF NICOTINIC AND MUSCARINIC BINDING-SITES IN ALZHEIMERS AND PARKINSONS DISEASES [J].
AUBERT, I ;
ARAUJO, DM ;
CECYRE, D ;
ROBITAILLE, Y ;
GAUTHIER, S ;
QUIRION, R .
JOURNAL OF NEUROCHEMISTRY, 1992, 58 (02) :529-541
[2]   Muscarinic cholinergic receptor measurements with [18F]FP-TZTP:: Control and competition studies [J].
Carson, RE ;
Kiesewetter, DO ;
Jagoda, E ;
Der, MG ;
Herscovitch, P ;
Eckelman, WC .
JOURNAL OF CEREBRAL BLOOD FLOW AND METABOLISM, 1998, 18 (10) :1130-1142
[3]  
CAULFIELD MP, 1982, LANCET, V2, P1277
[4]  
DANNALS RF, 1988, APPL RADIAT ISOTOPES, V39, P291
[5]   AGE-RELATED DECREASES IN MUSCARINIC CHOLINERGIC RECEPTOR-BINDING IN THE HUMAN BRAIN MEASURED WITH POSITRON EMISSION TOMOGRAPHY (PET) [J].
DEWEY, SL ;
VOLKOW, ND ;
LOGAN, J ;
MACGREGOR, RR ;
FOWLER, JS ;
SCHLYER, DJ ;
BENDRIEM, B .
JOURNAL OF NEUROSCIENCE RESEARCH, 1990, 27 (04) :569-575
[6]  
ECKELMAN WC, 1985, J NUCL MED, V26, P637
[7]   Vesicular acetylcholine transporter density and Alzheimer's disease [J].
Efange, SMN ;
Garland, EM ;
Staley, JK ;
Khare, AB ;
Mash, DC .
NEUROBIOLOGY OF AGING, 1997, 18 (04) :407-413
[8]   PET study of the M(1)-agonists [C-11]xanomeline and [C-11]butylthio-TZTP in monkey and man [J].
Farde, L ;
Suhara, T ;
Halldin, C ;
Nyback, H ;
Nakashima, Y ;
Swahn, CG ;
Karlsson, P ;
Ginovart, N ;
Bymaster, FP ;
Shannon, HE ;
Foged, C ;
Suzdak, PD ;
Sauerberg, P .
DEMENTIA, 1996, 7 (04) :187-195
[9]   Muscarinic receptor agonists in Alzheimer's disease - More than just symptomatic treatment? [J].
Fisher, A .
CNS DRUGS, 1999, 12 (03) :197-214
[10]   INVIVO MUSCARINIC CHOLINERGIC RECEPTOR IMAGING IN HUMAN BRAIN WITH [C-11] SCOPOLAMINE AND POSITRON EMISSION TOMOGRAPHY [J].
FREY, KA ;
KOEPPE, RA ;
MULHOLLAND, GK ;
JEWETT, D ;
HICHWA, R ;
EHRENKAUFER, RLE ;
CAREY, JE ;
WIELAND, DM ;
KUHL, DE ;
AGRANOFF, BW .
JOURNAL OF CEREBRAL BLOOD FLOW AND METABOLISM, 1992, 12 (01) :147-154